Introduction
tumor
TUMOR
Olaparib is an inhibitor of the poly (adenosine diphosphate–ribose) polymerase (PARP) family of enzymes, which exploits the principle of synthetic lethality to selectively kill tumor cells deficient in homologous recombination repair pathways, such as those harboring loss-of-function mutations in The multinational phase 3 OlympiA trial compared 1 year of adjuvant olaparib with placebo in patients with germline Results from the OlympiA study led to the approval of olaparib for the adjuvant treatment of adult patients with germline Here, we report the efficacy and safety of olaparib compared with placebo in the subset of patients from Japan and contextualize the findings with reference to the outcomes in the global OlympiA population.